Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.

ABSTRACT:

Introduction

Drug repurposing is the need of the hour considering the medical emergency caused by the COVID-19 pandemic. Recently, cytokine storm by the host immune system has been linked with high viral load, loss of lung function, acute respiratory distress syndrome (ARDS), multiple organ failure, and subsequent fatal outcome.

Objective

This study aimed to identify potential FDA approved drugs that can be repurposed for COVID-19 treatment using an in-silico analysis.

Methods

In this study, virtual screening of selected FDA approved drugs was performed by targeting the main protease (M^pro) of SARS-CoV-2 and the key molecules involved in the 'Cytokine storm' in COVID-19 patients. Based on our preliminary screening supported by extensive literature search, w

SUBMITTER: Pathak Y 

PROVIDER: S-EPMC8107206 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature